AlphAIAlphAI — Financial news for AI agents
investing.comOCT 292 min read$ESTA

Establishment Labs stock price target lowered to $93 by BTIG on estimates

BTIG lowered its price target on Establishment Labs (ESTA) to $93 from $103, maintaining a Buy rating. The company reported Q3 revenue of $72.0M, up 34% YoY, and adjusted EBITDA of $6.4M, exceeding estimates. ESTA raised its 2026 revenue guidance to at least $274M. The stock gained 8.6% over the past week, trading at $69.74. BTIG adjusted its 2027 and 2028 estimates due to a more conservative timeline for U.S. reconstruction approval.

Original reporting
investing.com
Published Oct 29, 2026, 7:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 7:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ESTA
Neutral
high confidence
Mentioned
$ESTA
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ESTANeutralMed
01

Why it matters

The earnings beat and guidance raise suggest operational strength, but the reduced price target signals valuation concerns, leading to mixed trader sentiment.

02

Market read

ESTA's earnings beat and guidance raise provide a catalyst for short‑term price movement, while the lower price target may temper upside expectations.

03

What to watch

The FDA approval of new implant sizes and potential label expansion may drive future revenue beyond current guidance.

Relevance 7/10Novelty 7/10Timing: post‑market today

Background

Establishment Labs (NASDAQ:ESTA) reported a 34% YoY revenue increase and its first free‑cash‑flow positive quarter, while BTIG reduced its 2027‑28 forecasts and lowered the price target.

Company-level read

Ticker impact

$ESTANeutralHigh confidence
Context

BTIG cut its price target to $93 after reporting Q3 revenue of $72M (up 34%) and raising full‑year 2026 revenue guidance to at least $274M.

Expected impact

potential modest pressure as the market prices in the lower target despite strong Q3 results

Evidence & confidence

The new target of $93 is below the current price (~$70) but reflects a 28% discount to the 52‑week high; investors may weigh the revenue beat against the reduced future forecasts.

Market effects

Sector

Positive earnings beat may lift other small‑cap medical‑device peers, but the lower price target could dampen sector sentiment.

Regional

Limited to U.S. small‑cap investors; no broader regional effect.

Global

Minimal global impact; primarily a micro‑cap specific event.

Counterpoint

What could challenge this read

Despite the lower price target, the strong revenue growth and first free‑cash‑flow positive quarter could justify a buy on the dip.

Key entities

  • analyst
    BTIG

    Equity research firm that lowered ESTA's price target to $93.

  • regulator
    FDA

    Approved additional Motiva implant sizes for ESTA.

Read at source← All news

StoryEstablishment Labs posts Q3 revenue beat, first positive free cash flow and raises 2026 guidance

Also covered by

3 outlets

Related articles

OCT 29
$ESTAMed

Establishment Labs Holdings Inc. Q3 2026 Earnings Call Summary

Establishment Labs reported Q3 2026 revenue growth of 33.9%, driven by U.S. market share gains and a 124% increase in minimally invasive revenue. The company achieved positive free cash flow and expects 25% revenue growth in 2027, supported by increased U.S. utilization and FDA approval for Motiva implants in reconstruction. Gross margin expansion of 50 to 100 basis points is projected for 2027, with growth driven by leadership optimization in international markets.

finance.yahoo.com6 min
OCT 29
$ESTAMed

What Establishment Labs (ESTA) Said on Its Q3 Earnings Call

Establishment Labs (ESTA) reported $75.8M in cash, targeting positive free cash flow for 2027. U.S. accounts grew to 2,100, with 30% market share. Minimally invasive revenue rose 124% YoY to $9M, raising full-year guidance to over $40M. International revenue increased 16% YoY, led by Europe. GAAP gross margin was 69.1%, with adjusted margin at 70.8%. The company prepares for potential FDA approval of Motiva implants for reconstruction.

finance.yahoo.com7 min
OCT 29
$ESTAHighAI 9/10

Establishment Labs® Reports Third Quarter 2026 Financial Results

ESTABLISHMENT LABS HOLDINGS INC. (ESTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Malavika William mwilliam@establishmentlabs.com Establishment Labs ® Reports Third Quarter 2026 Financial Results Revenue Increases 33.9% to $72.0 Million, Driven by 119% U.S. Growth Achieves First Quarter of Positive Operating a

SEC EDGAR 8-K6 min